This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Eli Lilly & Co (LLY) and C4 Therapeutics (CCCC)

Tipranks - Tipranks - Tue Jun 23, 3:46AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT), Eli Lilly & Co (LLY) and C4 Therapeutics (CCCC).

TipRanks' Prime Week Sale - 70% Off

Sarepta Therapeutics (SRPT)

Barclays analyst Eliana Merle maintained a Hold rating on Sarepta Therapeutics today and set a price target of $20.00. The company’s shares closed last Thursday at $17.53.

According to TipRanks.com, Merle is a 2-star analyst with an average return of 0.7% and a 41.9% success rate. Merle covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Ultragenyx Pharmaceutical, and Madrigal Pharmaceuticals. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $22.81 average price target, implying a 33.8% upside from current levels. In a report issued on June 18, RBC Capital also maintained a Hold rating on the stock with a $19.00 price target.

See the top stocks recommended by analysts >>

Eli Lilly & Co (LLY)

In a report released today, Emily Field from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $1400.00. The company’s shares closed last Thursday at $1098.57.

According to TipRanks.com, Field is a 3-star analyst with an average return of 1.4% and a 44.8% success rate. Field covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1289.33 average price target, which is a 15.1% upside from current levels. In a report issued on June 7, BMO Capital also maintained a Buy rating on the stock with a $1300.00 price target.

C4 Therapeutics (CCCC)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on C4 Therapeutics, with a price target of $7.00. The company’s shares closed last Thursday at $4.15.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 25.0% and a 55.6% success rate. Darout covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, Monopar Therapeutics Inc, and Protagonist Therapeutics. ;'>

C4 Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.33.

Read More on SRPT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).